Reference Pricing
-
340B, Affordable Care Act, Caught my eye, CMMI, Drug Prices, Drug shortages, Employers, Inflation Reduction Act, Medicare Negotiation, Medicare Transaction Facilitator, Pharmacy Benefit Managers, Preventative, Reference Pricing
Caught my eye — 5/16/25
Read more: Caught my eye — 5/16/25This week I’ve repeatedly spoken to groups about the President’s Executive Order (EO) on Most Favored Nation (MFN) pricing and I feel a little vulnerable. I am often “authentic” in my explanations. I recognize that to many people I seem biased on a lot of issues but, in my defense, I find most politics maddening…
-
Initial Take on MFN Executive Order, Part II
Read more: Initial Take on MFN Executive Order, Part IIInitial take at 3:30 today … which could change as I learn more… The foundational premise of the President’s new Executive Order (EO) is that the United States should pay less for drug and other countries should pay more; there should be an equalization. The Administration will take steps to work with foreign countries and…
-
Catch as Catch Can
Read more: Catch as Catch CanSection 4 of the President’s Executive Order (EO) on drug pricing aims to reduce the high-cost drugs for seniors through the development and implementation of a payment model. It is very light on details; basically a title and one run-on sentence. So wide in scope you could drive a truck through it, but let’s pull…
-
Caught my eye — 03/28/25
Read more: Caught my eye — 03/28/25There are some weeks you get to Friday and it’s just nice. The anticipation of some dopamine, some relaxation over the weekend. There are other weeks where you barrel into Friday and cram everything in so that 5 pm can arrive with a cocktail. Guess which week I’m having… three quick things you should know.…
-
Caught my eye — 12/13/24
Read more: Caught my eye — 12/13/24Methodology Matters. The Institute for Clinical and Economic Review (ICER) released their annual Unsupported Price Increase report and I find the whole process maddening. The inflationary metric they used was medical, not general (CPI-U). You might think that didn’t matter but it does. You know what medical inflation was? 0.48%. So anything over 2.48% increase…
-
340B, Caught my eye, Drug Prices, Employers, Healthcare Costs, ICER, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Medicare Transaction Facilitator, Reference Pricing, ValueCaught my eye — 5/10/24
Read more: Caught my eye — 5/10/24Back to back. Arnold Ventures put out the latest anti-pharma talking points (h/t Brian Reid) and here were two back to back – Here’s the problem, it really isn’t about the cost of drugs. I mean you could take that drug price and reduce it 98% and the 25% cost share would still be too…
-
Required Reading: Come on Down
Read more: Required Reading: Come on DownIt is rare for me to print things anymore; limited access to a giant corporate printer cuts down on the urge. But today I got the printer going, grabbed the highlighter and dug in. The paper? “Is the price right? Paying for value today to get more value tomorrow.” If I were a health policy…
-
Another bite at the apple
Read more: Another bite at the appleIt used to be that pharmaceutical manufacturers had to worry (mostly) about federal health policy. Every few years manage through a big piece of legislation from Congress and then the regulation on Medicare, Medicaid, the Affordable Care Act and any regulation that came out of the legislation. But over the past few years, the drug…
Latest news
- Caught my eye — 5/16/25
- Initial Take on MFN Executive Order, Part II
- Caught my eye — 5/09/25
- Don’t Call it a Comeback
- Caught my eye — 5/2/25
Categories
- 340B (38)
- Affordable Care Act (5)
- Alzheimer's (6)
- Biosimilars (22)
- Caught my eye (67)
- Cell and Gene (2)
- Chevron Deference (2)
- CMMI (14)
- Copay Accumulators (6)
- COVID (2)
- Drug Prices (36)
- Drug shortages (10)
- DTC (2)
- Employers (8)
- Generics (6)
- Health Equity (3)
- Healthcare Costs (30)
- ICER (10)
- Importation (4)
- Inflation Reduction Act (50)
- Insulin (5)
- IP (3)
- Long term care (1)
- Medicaid (7)
- Medicare Advantage (16)
- Medicare Negotiation (52)
- Medicare Part D (47)
- Medicare Transaction Facilitator (3)
- Medicare Transaction Facilitator (9)
- Obesity (21)
- On the Horizon (1)
- Orphan Drugs (3)
- Pharmacy Benefit Managers (32)
- Preventative (2)
- Reference Pricing (8)
- State-based Reform (16)
- Supply Chain (2)
- Uncategorized (7)
- Utilization Management (1)
- Vaccines (4)
- Value (13)